Key result
Evinacumab reduces LDL-C by ~47% versus placebo in patients with homozygous familial hypercholesterolemia.
Why the study?
Standard lipid-lowering therapies often fail to achieve recommended LDL-C targets in homozygous familial hypercholesterolemia due to impaired LDL receptor function.
Does evinacumab reduce LDL-C in patients with homozygous familial hypercholesterolemia?
Does evinacumab reduce LDL-C in patients with homozygous familial hypercholesterolemia?
Effect estimate: -49.0 percentage points
Absolute Event Rate: -47.1% vs 1.9%
p-value: p=<0.001
Evinacumab, an ANGPTL3 inhibitor, provides substantial LDL-C reductions of 45-50% in HoFH patients independent of LDL receptor activity, offering an effective option for those with inadequate response to conventional therapies.
Supports evinacumab via ANGPTL3 inhibition in HoFH; leaves open need for larger randomized outcome trials.
Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by extremely elevated low-density lipoprotein cholesterol (LDL-C) levels and a markedly increased risk of premature atherosclerotic cardiovascular disease. The aim of this review was to summarize current knowledge on the pathophysiology, diagnosis, and management of HoFH, with particular emphasis on angiopoietin-like protein 3 (ANGPTL3) inhibition and the clinical role of evinacumab. A comprehensive analysis of published clinical trials, guidelines, and observational studies was conducted to evaluate available diagnostic criteria and therapeutic strategies. Standard lipid-lowering therapies often fail to achieve recommended LDL-C targets in HoFH due to impaired LDL receptor function. Evinacumab, a fully human monoclonal antibody targeting ANGPTL3, has demonstrated substantial LDL-C reductions independent of LDL receptor activity in both adult and pediatric patients. Clinical studies report LDL-C reductions of approximately 45–50%, along with a favorable safety profile. In conclusion, ANGPTL3 inhibition with evinacumab represents a significant advancement in the treatment of HoFH, offering an effective therapeutic option for patients with inadequate response to conventional lipid-lowering therapies.
No takes yet. Share an insight, caveat, or question.
Majchrowicz et al. (2026) conducted a review in Homozygous familial hypercholesterolemia (HoFH). Evinacumab vs. Placebo was evaluated on Percentage change in LDL-C concentration at week 24 (-49.0 percentage points, p=<0.001). Evinacumab reduced LDL-C levels by 47.1% from baseline compared to a 1.9% increase with placebo in patients with homozygous familial hypercholesterolemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: